Kodiak Sciences Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Net Loss of $54.3 Million, EPS at $1.03, R&D Expenses Rise to $42.8 Million
Kodiak Sciences Inc. has released its financial results for the second quarter of 2025, revealing a net loss of $54.3 million, or $1.03 per share, compared to a net loss of $45.1 million, or $0.86 per share, in the same period of 2024. The company's cash position at the end of the second quarter stood at $104.2 million, which is expected to support operations into 2026. Research and development expenses for the quarter increased to $42.8 million from $32.5 million in the previous year, primarily due to heightened clinical activities related to the APEX, DAYBREAK, and GLOW2 studies. The quarter's R&D expenses included $7.7 million in non-cash stock-based compensation, down from $8.9 million in the second quarter of 2024. Kodiak Sciences also highlighted recent business developments, including promising new data from the KSI-101 APEX Phase 1b study, which underscores its potential in treating macular edema secondary to inflammation. Looking ahead, the company anticipates topline data from the Phase 3 study of its asset, tarcocimab, in the first and third quarters of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF51004) on August 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.